Data on the benefit of continuous glucose monitors (CGM) in people with diabetes not using intensive insulin therapy is limited. We describe clinical outcomes after a FreeStyle Libre® system purchase in people with type 2 diabetes (T2D) not using bolus insulin. IBM MarketScan™ Commercial Claims and Medicare Supplemental databases were used in this retrospective, observational analysis. MarketScan contains insurance billing claims for inpatient, outpatient, and pharmacy. Cohort requirements included: de novo CGM, FreeStyle Libre system purchase 2017 Q4-2018 Q4, T2D diagnosis, ≥18 years old, no fast-/short-acting insulin, ≥6-months pre-index observation time. Primary outcome was acute diabetes events (ADE): hospitalization with hyper-/hypoglycemia as primary diagnosis or outpatient emergency with same codes. Secondary outcome was all-cause hospitalization. Andersen-Gill Cox regression compared event rates 6-months pre-/post-index. The cohort (n= 7,167, age 53.3±9.5 years, 51.5% male, avg. post-index follow-up 155 days) saw a reduction in ADE from 0.071 to 0.052 events/pt-yr (HR: 0.70 [0.57 0.85]; P:<0.001). Hospitalizations reduced from 0.180 to 0.161 events/pt-yr (HR: 0.87 [0.78 0.98]; P: 0.025). After FreeStyle Libre system purchase, T2D patients not on bolus insulin had lower rates of ADE and all-cause hospitalization.
E. Miller: None. M.S.D. Kerr: Employee; Self; Abbott. G.J. Roberts: Employee; Self; Abbott. D. Souto: Employee; Self; Abbott. Y. Nabutovsky: Employee; Self; Abbott. E. Wright: Advisory Panel; Self; Abbott, Sanofi. Consultant; Self; Abbott, AstraZeneca, Bayer U.S., Boehringer Ingelheim Pharmaceuticals, Inc., MannKind Corporation, Merck & Co., Inc., Voluntis France. Speaker’s Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes.
